Cardiovascular Tests: Use & Limits of Biochemical Markers - Therapeutic Measurements of ADMA Involved in Cardiovascular Disorders

Authors: Smith, Caroline L.; Vallance, Patrick

Source: Current Drug Metabolism, Volume 11, Number 17, July 2005 , pp. 2177-2185(9)

Publisher: Bentham Science Publishers

Buy & download fulltext article:

Price: $63.10 plus tax (Refund Policy)

Abstract:

Asymmetric dimethylarginine (ADMA) is an endogenously occurring methylarginine that inhibits nitric oxide synthesis. Plasma levels of methylarginines increase in renal failure and certain cardiovascular pathologies, and in patients with end stage renal failure the level of ADMA predicts the risk of cardiovascular events and overall mortality. The object of this review is to describe the mechanisms of ADMA synthesis, metabolism and uptake and to outline techniques for measuring ADMA and the pathological states in which ADMA levels are altered.

Keywords: nitric oxide (no); nitric oxide synthases (nos); nadph; protein arginine methyltransferases (prmt); single nucleotide polymorphisms (snp); angiogenesis; arginine; cardiovascular disorders; pre-eclampsia

Document Type: Review article

DOI: http://dx.doi.org/10.2174/1381612054367364

Affiliations: 1: Centre for Clinical Pharmacology and Therapeutics, British Heart Foundation Laboratories, Department of Medicine, University College London, 5, University Street, London. WC1E 6JJ.

Publication date: 2005-07-01

More about this publication?

Current Pharmaceutical Design publishes timely in-depth reviews covering all aspects of current research in rational drug design. Each issue is devoted to a single major therapeutic area. A Guest Editor who is an acknowledged authority in a therapeutic field has solicits for each issue comprehensive and timely reviews from leading researchers in the pharmaceutical industry and academia.

Each thematic issue of Current Pharmaceutical Design covers all subject areas of major importance to modern drug design, including: medicinal chemistry, pharmacology, drug targets and disease mechanism.